Previous 10 | Next 10 |
LONDON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter and year-end 20...
COMPASS Pathways ADS ( NASDAQ: CMPS ) is scheduled to announce Q4 earnings results on Monday, February 27th, after market close. The consensus EPS Estimate is -$0.63 (vs. -$0.61 last year) and the consensus Revenue Estimate is $0M. Over the last 1 year, CMPS has beaten ...
Summary There have been some exciting developments in the research around the medicinal potential of psychedelic compounds. Despite a potential opportunity for disruption, investors should keenly understand the unique risks to biotechnology plays before investing in the space. Given...
LONDON, Feb. 24, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter and year-end 2022, and ...
Scores of studies on the therapeutic potential of psychedelic substances have been conducted these last 20 years, with promising results showing that drugs such as MDMA, LSD and psilocybin may be useful in the treatment of various mental health conditions. These positive findings have fueled ...
After decades of criminalization by federal and state governments, psychedelics are finally seeing their day in the sun. Early research into psychedelics carried out in the late 1950s and early 1960s revealed that these substances may have some mental health benefits, but criminalization preven...
Australia recently made history when it categorized psychedelics as medicines, becoming the first country in the world to grant the distinction to hallucinogenic drugs. Psychedelics have been subject to an increasing amount of research in recent years amid a rising push for alternative mental...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Psychedelic stocks have seen remarkable progress in recent years, evolving from a fad to mainstream medicine. Several pharmaceutical companies are now investigating their potential therapeutic value. They’re also followi...
Dozens of states have launched medical and recreational cannabis industries over the past two decades amid a wave of drug reform that has swept across the country. In the past couple of years, reformists in several states have also begun campaigns to legalize, or at least decriminalize, psyched...
Summary Compass is a newly founded British company that is moving to commercialize the long-studied therapeutic impact of psilocybin. Both market acceptance issues and bad trip potential are risks of its psilocybin-based therapy. Compass has limited liquidity and will need significa...
News, Short Squeeze, Breakout and More Instantly...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...
New research has determined that psilocybin may impact the brain. Psilocybin is the primary psychoactive compound found in hallucinogenic mushrooms. When ingested, it distorts an individual’s perception of time, among other changes. Researchers have observed that in animals, psilocyb...